Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
Unicycive Therapeutics (UNCY) presented multiple studies at ASN Kidney Week 2024, highlighting progress on oxylanthanum carbonate (OLC) and UNI-494. The late-breaking presentation showed OLC enabled serum phosphate control in >90% of chronic kidney disease patients on dialysis who entered maintenance phase, with 69% achieving target levels at ≤1500 mg/day. The company also presented positive Phase 1 safety data for UNI-494. Two recent publications featured preclinical studies for both compounds. OLC demonstrated synergistic effects when combined with tenapanor in rat studies, while UNI-494 showed potential in treating acute kidney injury.
Unicycive Therapeutics (UNCY) ha presentato numerosi studi all'ASN Kidney Week 2024, evidenziando i progressi su ossilanthanato di carbonato (OLC) e UNI-494. La presentazione dell'ultimo minuto ha mostrato che OLC ha consentito il controllo del fosfato sierico in oltre il 90% dei pazienti con malattia renale cronica in dialisi che sono entrati nella fase di mantenimento, con il 69% che ha raggiunto i livelli target a ≤1500 mg/giorno. L'azienda ha anche presentato dati di sicurezza positivi di Fase 1 per UNI-494. Due pubblicazioni recenti hanno trattato studi preclinici per entrambi i composti. OLC ha dimostrato effetti sinergici quando combinato con tenapanor in studi su ratti, mentre UNI-494 ha mostrato potenziale nel trattamento dell'infortunio renale acuto.
Unicycive Therapeutics (UNCY) presentó múltiples estudios en la ASN Kidney Week 2024, destacando los avances en carbonato de oxilanthano (OLC) y UNI-494. La presentación de última hora mostró que OLC permitió el control del fosfato sérico en más del 90% de los pacientes con enfermedad renal crónica en diálisis que entraron en fase de mantenimiento, con un 69% alcanzando niveles objetivo de ≤1500 mg/día. La empresa también presentó datos de seguridad positivos de Fase 1 para UNI-494. Dos publicaciones recientes presentaron estudios preclínicos para ambos compuestos. OLC demostró efectos sinérgicos cuando se combinó con tenapanor en estudios con ratas, mientras que UNI-494 mostró potencial en el tratamiento de lesiones renales agudas.
유니사이브 테라퓨틱스 (UNCY)는 2024년 ASN Kidney Week에서 여러 연구 결과를 발표하며 옥실란타넘 탄산염 (OLC) 및 UNI-494의 진행 상황을 강조했습니다. 긴급 발표에서 OLC는 유지 치료 단계에 진입한 만성 신장 질환 환자 가운데 90% 이상에서 혈청 인산염 조절을 가능하게 하였으며, 69%는 목표 수준인 ≤1500 mg/일에 도달했습니다. 회사는 또한 UNI-494에 대한 긍정적인 1상 안전성 데이터를 발표했습니다. 두 개의 최근 출판물은 두 화합물에 대한 전임상 연구를 다루었습니다. OLC는 쥐 연구에서 테나파노르와 결합했을 때 시너지 효과를 나타냈고, UNI-494는 급성 신장 손상 치료의 잠재력을 보였습니다.
Unicycive Therapeutics (UNCY) a présenté plusieurs études lors de l'ASN Kidney Week 2024, soulignant les progrès réalisés sur le carbonate d'oxylanthanum (OLC) et UNI-494. La présentation de dernière minute a montré que l'OLC permettait de contrôler le phosphore sérique chez plus de 90% des patients atteints de maladie rénale chronique sous dialyse qui étaient entrés en phase de maintien, avec 69% atteignant les niveaux cibles de ≤1500 mg/jour. L'entreprise a également présenté des données de sécurité positives de Phase 1 pour UNI-494. Deux publications récentes ont présenté des études précliniques pour les deux composés. L'OLC a démontré des effets synergiques lorsqu'il était combiné avec le téna-panore dans des études sur des rats, tandis qu'UNI-494 a montré un potentiel dans le traitement des lésions rénales aiguës.
Unicycive Therapeutics (UNCY) präsentierte auf der ASN Kidney Week 2024 mehrere Studien und hob die Fortschritte bei Oxylanthanumcarbonat (OLC) und UNI-494 hervor. Die Nachmeldungspräsentation zeigte, dass OLC bei über 90 % der an Dialyse leidenden Patienten mit chronischer Nierenerkrankung, die in die Erhaltungsphase eintraten, die Kontrolle des Serumphosphats ermöglichte, während 69 % die Zielwerte von ≤1500 mg/Tag erreichten. Das Unternehmen präsentierte auch positive Sicherheitsdaten der Phase 1 für UNI-494. Zwei aktuelle Publikationen befassten sich mit präklinischen Studien zu beiden Verbindungen. OLC zeigte synergetische Effekte in Kombination mit Tenapanor in Rattenstudien, während UNI-494 Potenzial bei der Behandlung akuter Nierenschäden zeigte.
- OLC achieved serum phosphate control in >90% of CKD patients on dialysis in pivotal trial
- 69% of patients reached target phosphate levels with ≤1500 mg/day of OLC
- UNI-494 Phase 1 study demonstrated safety and tolerability across all doses
- NDA submission completed for OLC
- None.
Insights
The clinical trial results for OLC represent significant progress in treating hyperphosphatemia in CKD patients on dialysis. The 90% success rate in achieving phosphate control with OLC, particularly with 69% of patients requiring ≤
The combination study of OLC with tenapanor showing synergistic effects (3.3x greater than tenapanor alone) suggests potential for enhanced treatment options. The Phase 1 results for UNI-494 also show promise, with therapeutic levels achieved and good safety profile, setting the stage for Phase 2 trials in kidney injury prevention.
This comprehensive data presentation strengthens Unicycive's market position in the nephrology space. With an NDA submitted for OLC and positive Phase 1 results for UNI-494, the company is advancing two potentially valuable assets. The hyperphosphatemia market represents a significant opportunity, as millions of CKD patients on dialysis require phosphate control. The demonstrated efficacy and lower dosing requirements could provide competitive advantages over existing treatments.
The successful development of both products could significantly impact the company's
– Late-Breaker Poster Presentation Highlights Favorable Safety & Tolerability of OLC –
– Two Publications Recently Issued Featuring OLC and UNI-494 –
LOS ALTOS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that multiple presentations were delivered at the American Society of Nephrology (ASN) Kidney Week 2024 that highlighted the extensive development progress for both oxylanthanum carbonate (OLC) and UNI-494.
“Kidney Week was extremely productive for us featuring a late-breaking presentation on our OLC pivotal trial, and our numerous data presentations were well received by the medical community,” said Shalabh Gupta, MD, Chief Executive Officer of Unicycive. “We were excited to present our positive pivotal clinical trial data demonstrating that OLC enabled adequate control of serum phosphate in more than
Dr. Gupta continued, “Earlier this month, we announced the successful competition of our UNI-494 Phase 1 study and were pleased to present the safety and tolerability data at ASN. We plan to request a meeting with the FDA before the end of the year to review these Phase 1 results and a potential Phase 2 study design.”
“For patients with CKD on dialysis, achieving adequate serum phosphate control is critically important because it can lead to other major complications including cardiovascular disease. I am encouraged by the results from the OLC pivotal trial presented at Kidney Week, and I believe that a product like OLC could have a meaningful impact on the overall care of CKD patients on dialysis,” added Dr. Pablo Pergola, MD, PhD, Research Director of the Clinical Advancement Center, PLLC, and a member of Renal Associates PA, San Antonio, Texas.
PUBLICATIONS
In addition to the presentations at ASN, preclinical studies for both OLC and UNI-494 were recently featured in two publications.
- “Systemic Absorption of Oxylanthanum Carbonate is Minimal in Preclinical Models” was published in the Pharmaceutical Chemistry Journal.
- “Evaluation of UNI-494 in Acute Kidney Injury Treatment Efficacy When Administered After Ischemia-Reperfusion in a Rat Model” was published in EC Pharmacology and Toxicology.
ASN KIDNEY WEEK PRESENTATIONS
Title: | Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia |
Lead Author: | Geoffrey A. Block, MD, FASN, Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs, U.S. Renal Care |
Summary: | This late-breaking poster describes the pivotal Phase 2 open-label, single-arm, multicenter, multidose study in adult patients with CKD with hyperphosphatemia receiving maintenance hemodialysis. The aim of the study was to assess the tolerability and safety of OLC at doses that achieve satisfactory serum phosphate control of ≤5.5 mg/dl. Most patients ( |
Title: | Combination Oxylanthanum Carbonate and Tenapanor Lowers Urinary Phosphate Excretion in Rat |
Lead Author: | Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive |
Summary: | This study evaluated the effects of OLC plus tenapanor on urinary phosphate excretion in rats on a high phosphorus diet. The study showed that the combination of OLC and tenapanor may support a pronounced inhibition of intestinal phosphate absorption by leveraging two distinct mechanisms of action: OLC, an intestinal phosphate binder, and tenapanor, a sodium/hydrogen exchanger (NHE3) blocker that diminishes transcellular phosphate absorption. The results demonstrated that the OLC plus tenapanor combination achieved a much more pronounced reduction in urinary phosphate excretion as compared to OLC alone and 3.3 times greater than tenapanor alone. In addition, the OLC plus tenapanor combination exhibited four- to seven-fold more synergistic effects compared to the sevelamer plus tenapanor combination. The study demonstrated potent effects of the novel lanthanum-based phosphate binder OLC and found that OLC plus tenapanor has synergistic, rather than additive, effects in rats. |
Title: | UNI-494 Phase I Safety, Tolerability, and Pharmacokinetics |
Lead Author: | Guru Reddy, PH.D., Vice President of Preclinical R&D, Unicycive |
Summary: | The poster described the results from the single ascending dose (SAD) cohorts from the Phase 1 study evaluating safety, tolerability, and pharmacokinetics (PK) of UNI-494 capsules administered to healthy volunteers. The study was a single-center, double-blind, placebo-controlled, randomized study that enrolled up to 40 subjects in 5 cohorts of 8 subjects each (6 active/2 placebo per cohort). Safety assessments and pharmacokinetics and systemic exposure of UNI-494 and its metabolites (nicorandil and CHEA) were evaluated. The data demonstrated that a single dose of 10-160 mg of UNI-494 capsules were safe and well-tolerated, and that UNI-494 was rapidly converted to nicorandil and the exposure to nicorandil increased in a dose-proportional manner. Therapeutic levels (AUC >200 hour*ng/mL) of nicorandil were achieved at 160 mg of UNI-494. This rapid conversion of UNI-494 to nicorandil and 1-cyclohexylethylamine indicates a potential for a fast-acting therapy for the prevention of Delayed Graft Function (DGF) and other acute kidney injury (AKI) clinical conditions. |
Title: | Intravenous UNI-494 Slows the Progression or Halts/Reverses Acute Kidney Injury When Administered After Ischemia/Reperfusion in Rats |
Lead Author: | Satya Medicherla, Ph.D., Vice President, Preclinical Pharmacology, Unicycive |
Summary: | The poster presented the results from a study evaluating the in vivo efficacy of intravenous (IV) UNI-494 when administered therapeutically after unilateral renal ischemia-reperfusion (I/R) in a rat model of AKI, which is a well-established model of DGF. The study showed that single IV doses of 10 mg/kg of UNI-494 administered after I/R significantly reduced serum and urinary AKI markers and improved proximal tubular injury scores. Specifically, a single IV dose of 10 mg/kg of UNI-494 improved key kidney functional markers (serum creatinine, blood urea nitrogen, urinary samples collected for albumin-creatinine ratio), the tubular injury marker neutrophil gelatinase-associated lipocalin, and proximal tubular injury scores. These data indicate therapeutic administration of UNI-494 slows down and may even halt or reverse AKI progression. |
The posters and publications can be found on the Unicycive Therapeutics website here.
About Oxylanthanum Carbonate (OLC)
Oxylanthanum carbonate is a next-generation lanthanum-based phosphate binding agent utilizing proprietary nanoparticle technology being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD). OLC has over forty issued and granted patents globally. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden for patients in terms of number and size of pills per dose that are swallowed instead of chewed. Based on a survey conducted in 2022, Nephrologists stated that the greatest unmet need in the treatment of hyperphosphatemia with phosphate binders is a lower pill burden and better patient compliance.1 The global market opportunity for treating hyperphosphatemia is projected to be in excess of
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. As part of the clinical development program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability. The second study was a randomized, open-label, two-way crossover bioequivalence study to establish pharmacodynamic bioequivalence between OLC and Fosrenol. Based on the results of the bioequivalence study, pharmacodynamic (PD) bioequivalence of OLC to Fosrenol was established. A pivotal clinical trial was also conducted in CKD patients on hemodialysis that achieved the study objective and established favorable tolerability of OLC at clinically effective doses.
Fosrenol® is a registered trademark of Shire International Licensing BV.
1Reason Research, LLC 2022 survey. Results here.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). If left untreated, hyperphosphatemia leads to secondary hyperparathyroidism (SHPT), which then results in renal osteodystrophy (a condition similar to osteoporosis and associated with significant bone disease, fractures and bone pain); cardiovascular disease with associated hardening of arteries and atherosclerosis (due to deposition of excess calcium-phosphorus complexes in soft tissue). Importantly, hyperphosphatemia is independently associated with increased mortality for patients with chronic kidney disease on dialysis. Based on available clinical data to date, over
Dialysis patients are already at an increased risk for cardiovascular disease (because of underlying diseases such as diabetes and hypertension), and hyperphosphatemia further exacerbates this. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
About UNI-494
UNI-494 is a novel nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator. Mitochondrial dysfunction plays a critical role in the progression of acute kidney injury and chronic kidney disease. UNI-494 has a novel mechanism of action that restores mitochondrial function and may be beneficial for the treatment of several diseases including kidney disease. Unicycive has completed enrollment in the UNI-494 Phase 1 dose-ranging safety study in healthy volunteers in the United Kingdom. UNI-494 is protected by issued patent(s) in the U.S. and Europe and a wide range of patent applications worldwide. UNI-494 has been granted orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the prevention of Delayed Graft Function (DGF) in kidney transplant patients.
About Acute Kidney Injury
Acute kidney injury (AKI) is defined as a sudden loss of kidney function that is determined based on increased serum creatinine levels and decreased urine output and is limited to a duration of 7 days. The primary causes of AKI include sepsis, ischemia, hypoxia, and drug-induced nephrotoxicity. Delayed Graft Function is a type of acute kidney injury that occurs in the first week after kidney transplantation. AKI is estimated to occur in 20-200 per million population in the community, 7
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn, X, and YouTube.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contact:
ir@unicycive.com
(650) 543-5470
SOURCE: Unicycive Therapeutics, Inc.
FAQ
What were the key results of Unicycive's (UNCY) OLC pivotal trial presented at ASN Kidney Week 2024?
What were the Phase 1 results for Unicycive's (UNCY) UNI-494?